US 7358259
HCV inhibitors and methods of using them
granted A61PA61P1/16A61P31/12
Quick answer
US patent 7358259 (HCV inhibitors and methods of using them) held by Rigel Pharmaceuticals, Inc. expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Apr 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61P, A61P1/16, A61P31/12